{"id":47755,"date":"2026-07-30T02:00:00","date_gmt":"2026-07-30T00:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=be7a649edfabd4295d1ef792f8caaf30"},"modified":"2026-07-30T02:00:00","modified_gmt":"2026-07-30T00:00:00","slug":"sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=47755","title":{"rendered":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta\u2019s 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to employment to Michael Severino, M.D. as Chief Executive Officer of Sarepta. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p><\/a><\/a>

\nDr. Severino received options to purchase 2,224,342 shares of Sarepta\u2019s common stock (\u201cOptions\u201d), and 756,104 restricted stock units (\u201cRSUs\u201d). The options have an exercise price of $17.74 per share, which is equal to a 15% premium to the closing price of Sarepta\u2019s common stock on July 28, 2026 (the \u201cGrant Date\u201d). One-fourth of Dr. Severino\u2019s Options will vest on the one-year anniversary of the Grant Date and thereafter 1\/48th of Dr. Severino\u2019s Options will vest monthly, such that the Options will be fully vested on the fourth anniversary of the Grant Date, in each case, generally subject to Dr. Severino\u2019s continued employment with Sarepta on such vesting dates. One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to Dr. Severino will be fully vested on the fourth anniversary of the Grant Date, generally subject to Dr. Severino\u2019s continued employment with Sarepta on such vesting date.<\/p>

\nAbout Sarepta Therapeutics\n<\/i><\/strong>Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com<\/b><\/a> or follow us on LinkedIn<\/b><\/a>, X<\/b><\/a>, Instagram<\/b><\/a> and Facebook<\/b><\/a>.<\/p>

\nInternet Posting of Information\n<\/i><\/strong>We routinely post information that may be important to investors in the 'For Investors' section of our website at <\/i>www.sarepta.com<\/i><\/a>. We encourage investors and potential investors to consult our website regularly for important information about us.<\/i><\/p> Contacts<\/b>

\nInvestor Contact:<\/i><\/b>Ian Estepan, 617-274-4052 iestepan@sarepta.com<\/a>Ryan Wong, 617-800-4112, rwong@sarepta.com<\/a>Tam Thornton, 617-803-3825, tthornton@sarepta.com<\/a><\/p>

\nMedia Contact:<\/i><\/b>Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta\u2019s 202…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-47755","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/47755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47755"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/47755\/revisions"}],"predecessor-version":[{"id":47757,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/47755\/revisions\/47757"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}